scholarly journals Retinitis Pigmentosa Treatment with Western Medicine and Traditional Chinese Medicine Therapies

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Jian Xu ◽  
Qinghua Peng

Current management of retinitis pigmentosa (RP) includes an attempt at slowing down the degenerative process through therapies that use either Western or traditional Chinese medicine (TCM). Novel therapies in Western medicine (WM) include use of tailor-made gene therapy, transplantation of stem cells, or neuroprotection treatment. TCM treatment includes two major approaches. These are orally applied herbal decoctions and acupuncture. In fact, all TCM treatments are based on the differentiation of a symptom-complex, which is the characteristic essence of TCM. Thus, diagnosed RP may be treated via the liver, the kidney, and the spleen. The principle behind these treatments is to invigorate the blood and brighten the eyes by toning up the liver and the kidney. Also treatments to cope with deficiencies in the two concepts that are unique and fundamental to TCM are considered: Qi or “vital energy” and Yin and Yang or the harmony of all the opposite elements and forces that make up existence. In particular, the Qi deficiency that results from blood stasis is addressed in these treatments. This paper also puts forward the existing problems and the prospect of the future development on integrating TCM with WM.

2022 ◽  
Vol 67 (4) ◽  
pp. 121-129
Author(s):  
Tan Zifu ◽  
Li Jiaquan ◽  
Zhang Juan

The pathological basis of non-ST-segment elevation acute coronary syndrome (NSTE-ACS) is severe coronary stenosis, unstable plaque erosion, and rupture, resulting in coronary blood flow reduction and myocardial ischemia, leading to acute thrombosis cardiovascular disease events. This subject intends to study the treatment of NSTE-ACS patients with blood stasis and toxin syndrome by Qingre Jiedu Huoxue Huayu Decoction, observe its clinical efficacy, and explore the effects of serum lipoprotein phospholipase A2 (Lp-PLA2) and tumor necrosis factor- α (TNF- α), the effect of placental growth factor (PIGF) expression. In this study, 100 patients with blood stasis and toxin syndrome of NSTE-ACS treated in the cardiovascular department of Enshi National Hospital from August 2020 to August 2021 were selected as the research object. They were randomly divided into traditional Chinese medicine comprehensive treatment groups and conventional western medicine control groups, with 50 cases. The conventional western medicine control group was treated with hydroclopidogrel tablets orally, and the comprehensive treatment group of traditional Chinese medicine combined with Qingre Jiedu Huoxue Huayu formula orally. The patients in both groups were treated for four weeks. The results showed that after treatment, the practical clinical rate of the comprehensive treatment group was significantly higher than that of the conventional western medicine control group. After treatment, the TCM syndrome score, angina pectoris attack duration, and angina pectoris attack frequency, myocardial zymogram index level, serum Lp-PLA2 and TNF of the two groups were measured- α. The levels of PIGF were significantly lower than those before treatment. The decline of the above indexes in the comprehensive treatment group of traditional Chinese medicine was significantly better than that in the control group of conventional Western Medicine (P<0.05). The incidence of MACE events in the TCM Comprehensive treatment group was significantly lower than that in the conventional western medicine control group (P <0.05).


Author(s):  
Weibo LU

LANGUAGE NOTE | Document text in Chinese; abstract also in English.中西醫結合包含中醫和西醫之間的團結合作,但更重要的是中醫學和西醫學之間的互相結合。在世界上對傳統醫學曾有過三種方針,即“否定”,“容忍”和“平行”的方針,均不能充分發揮傳統醫學的作用和潛力。中國採取“結合”的方針,較好地解決了這一問題,不僅滿足當前醫療工作的需要,更重要的是在科學研究中,強調創新,兩種醫學的觀點、方法、優勢互補,獲得大量新的研究成果,如針刺原理和針麻研究,青萬素的發現,瘀血證研究等。雖然現代醫學是主流醫學,但尚不足以解決所有問題,如慢性病,老年病等。用結合的思想可以更好地解決各種難題,使醫學科學更快地向前發展,造福於人民。What attitude should we take toward traditional medicine? There have been three types of policies in this regard all over the world. First, the excluding policy prohibits practicing any traditional medicine. Traditional physicians are not qualified to possess the title of physician, and their practice is illegal. Second, the tolerating policy does not make illegal traditional medical practice, but it does not formally affirm the practice. Third, the paralleling policy allows both traditional and modem medical practices, but their use may not overlap. For example, traditional physicians may not use modem medical facilities.Since the establishment of the People’s Republic of China in 1949, a unique policy of integration has been adopted in China. This policy assumes that both traditional Chinese medicine and modern Western medicine have strengths and weaknesses. It requires that both types of medicine be integrated so as to develop more effective methods in treating diseases and preserving health.There are two senses of the integration of traditional Chinese and modern Western medicine. The first sense refers to the integration of the two types of the physicians, i.e., the cooperation between traditional Chinese practitioners and modern Western medical professionals. The second sense refers to the integration of the two disciplines; i.e., to use both traditional Chinese and modern Western medical theories and practices to create new forms of diagnostic and therapeutic approaches and means. The hope was to have the perspectives, methods, and solutions of both types of medicine complement each other.Under the integrating policy, traditional Chinese medicine has been developed tremendously in mainland China. 30 traditional Chinese medical colleges, 2457 traditional Chinese medical hospitals, and 170 traditional Chinese medical research institutions have been established. A number of well-known medical achievements, such as acupunctural analgesia and anesthesia, the discovery of a new type of anti-malaria drug - Qinghaosu (artemisinin), and the study of blood stasis syndrome, have been made by following the integrating strategy.With the rapid growth and development of the diagnostic and therapeutic technologies in modern Western medicine, some individuals are doubtful of the prospect of traditional Chinese medicine and of the necessity of China’s integrating strategy. However, no matter how advanced modern Western medicine as a form of medicine has become, it will not be able to handle all diseases or medical problems effectively and appropriately. The human body and medical reality are too complicated to be fixed by modern medicine once and for all. For instance, in the present time, chronic and geriatric diseases pose perplexing challenges to modern medicine. Possibilities are always open for traditional Chinese medicine as well as the integrated traditional Chinese and modern medicine to make their valuable contributions.DOWNLOAD HISTORY | This article has been downloaded 69 times in Digital Commons before migrating into this platform.


2021 ◽  
Vol 5 (5) ◽  
pp. 33-36
Author(s):  
Yuan Cheng ◽  
Jichao Yin ◽  
Xinglv Hu ◽  
Penggang Xu ◽  
Yingchun Liu ◽  
...  

The theory of yin and yang in Chinese medicine signifies everything and can be used to divide everything in the world. The diagnosis and assessment of ankylosing spondylitis in Western medicine can also be divided by yin and yang. The current technologies used in Western medicine for detecting ankylosing spondylitis is summarized, divided, and reasoned with the philosophical views of yin and yang in traditional Chinese medicine.


2014 ◽  
Vol 2014 ◽  
pp. 1-19 ◽  
Author(s):  
Jie Wang ◽  
Xingjiang Xiong ◽  
Wei Liu

Background. To simplify traditional Chinese medicine syndrome differentiation and allow researchers to master syndrome differentiation for hypertension, this paper retrospectively studied the literature and analyzed syndrome elements corresponding to hypertension syndromes.Methods. Six databases including PubMed, EMBASE, Chinese Bio-Medical Literature Database, Chinese National Knowledge Infrastructure, Chinese Scientific Journal Database, and Wan-fang Data were searched from 1/January/2003 to 30/October/2013. We included all clinical literature testing hypertension syndromes and retrospectively studied the hypertension literature published from 2003 to 2013. Descriptive statistics calculated frequencies and percentages.Results. 13,272 patients with essential hypertension were included. Clinical features of hypertension could be attributed to 11 kinds of syndrome factors. Among them, seven syndrome factors were excess, while four syndrome factors were deficient. Syndrome targets were mainly in the liver and related to the kidney and spleen. There were 33 combination syndromes. Frequency of single-factor syndromes was 31.77% and frequency of two-factor syndromes was 62.26%.Conclusions. Excess syndrome factors of hypertension patients include yang hyperactivity, blood stasis, phlegm turbidity, internal dampness, and internal fire. Deficient syndrome factors of hypertension patients are yin deficiency and yang deficiency. Yin deficiency with yang hyperactivity, phlegm-dampness retention, and deficiency of both yin and yang were the three most common syndromes in clinical combination.


2020 ◽  
Author(s):  
Li Lin ◽  
Yuan Wang ◽  
Sennan Shao ◽  
Wen Lin ◽  
Dan Huang ◽  
...  

Abstract Background: The combination of traditional Chinese medicine and western medicine is commonly accepted in clinics in China. Shaoyao-Gancao-Fuzi decoction (SGFD) has been extensively used to dispel wind, eliminate dampness and treat paralysis. Tofacitinib is approved for the treatment of rheumatoid arthritis. SGFD and tofacitinib could be used together for the treatment of rheumatoid arthritis.Methods: A cocktail approach was employed to assess the effects of SGFD on the activities of CYP450s. After pretreatment for 2 weeks with SGFD, a cocktail solution was given to rats 24 h after the last dose of saline or SGFD. Additionally, the pharmacokinetic profiles of oral administration of tofacitinib in rats, with or without SGFD pre-treatment were investigated.Results: The results showed that SGFD could induce the activity of CYP1A2 and inhibit the activity of CYP3A4. Furthermore, SGFD could significantly affect the pharmacokinetics of tofacitinib. Compared with control group, the AUC0-∞ of tofacitinib was increased from 13669.53 ± 4986.83 to 28706.69 ± 9563.13 ng/mL*h (p < 0.01), and the Cmax was increased from 8359.66 ± 1512.22 to 11332.51 ± 2791.90 ng/mL (p < 0.05).Conclusions: The system exposure of tofacitinib was increased by SGFD. The mechanism might be through inhibiting the activity of CYP3A4 and reducing the metabolism of tofacitinib in rats. The study will provide better guidance for the safe clinical use of SGFD and tofacitinib.


Sign in / Sign up

Export Citation Format

Share Document